Part 9 · Module 5
Control Groups, Placebos and Standard Care
Choose ethical and clinically meaningful control groups, including placebo, active treatment, attention control and standard care.
Learning outcomes
After completing this lecture, you should be able to:
- Define the treatment contrast created by each comparator.
- Distinguish placebo, active, sham, attention and usual-care controls.
- Assess equipoise, rescue treatment and standard-of-care variation.
- Avoid comparator changes that undermine interpretation.
- Describe both intervention and control conditions reproducibly.
Overview
A trial effect is defined relative to its comparator. Placebo, active treatment, standard care, wait-list, attention control and sham procedures answer different questions. The control condition must be ethically acceptable, sufficiently specified and relevant to the decision the trial is intended to inform.
The study question, design, participant pathway, measurements and analysis must be specified as one coherent system. A recognised design label is useful only when the operational details preserve the comparison or prediction that the study is intended to support.[1–3]
Why this matters
“Usual care” can vary by site, clinician and calendar time. An attention control may equalise contact but introduce active behaviour change. A placebo can isolate a specific pharmacological component but may not answer whether a new treatment is better than effective current therapy.
Core concepts
Comparator choice determines the estimand
Navigation versus routine care estimates the effect of offering the whole package over current practice. Navigation versus reminder-only estimates the incremental contribution of counselling and booking. Neither is universally “the” treatment effect.
Placebo controls isolate specific effects
A placebo mimics treatment experience without the specific active component. It can help distinguish pharmacological effects from expectations and natural history but may be unethical when effective therapy must not be withheld.
Active controls support comparative effectiveness
A new intervention can be compared with an established treatment. Superiority, non-inferiority or equivalence objectives require different assumptions, margins and evidence that the active comparator was delivered effectively.
Attention and wait-list controls have behavioural consequences
Equal contact can reduce differential expectations but may itself affect outcomes. Wait-list controls guarantee later access but do not control for attention and may change participant behaviour while waiting.
Standard care must be measured
Define required and prohibited components, expected variation and policy context. Changes during the trial should be tracked because the comparator can drift, narrowing or widening the contrast.
When to use this approach
Choosing the control condition
- What decision will the trial inform after completion?
- Is effective therapy already available and ethically required?
- Which nonspecific effects need control?
- Could the comparator itself change behaviour or outcomes?
- How variable is standard care across sites and time?
Working through the key design decisions
Decision 1: What decision will the trial inform after completion?. This point should be resolved before recruitment, extraction or assignment begins. For control groups, placebos and standard care, the protocol should state the operational rule, who applies it, when it is applied and what source documents demonstrate compliance. The investigators should also consider how a different choice would change the eligible population, comparison, timing, measurement or interpretation. A pilot review of realistic records or participant pathways can reveal ambiguities before they become irreversible exclusions or post hoc analytical choices. The decision should be reviewed across sites and subgroups because a rule that works in one clinic may operate differently where referral, resources or disease spectrum differ. Any permitted exception should be explicit, dated and reported with its frequency and likely consequence.
Decision 2: Is effective therapy already available and ethically required?. This point should be resolved before recruitment, extraction or assignment begins. For control groups, placebos and standard care, the protocol should state the operational rule, who applies it, when it is applied and what source documents demonstrate compliance. The investigators should also consider how a different choice would change the eligible population, comparison, timing, measurement or interpretation. A pilot review of realistic records or participant pathways can reveal ambiguities before they become irreversible exclusions or post hoc analytical choices. The decision should be reviewed across sites and subgroups because a rule that works in one clinic may operate differently where referral, resources or disease spectrum differ. Any permitted exception should be explicit, dated and reported with its frequency and likely consequence.
Decision 3: Which nonspecific effects need control?. This point should be resolved before recruitment, extraction or assignment begins. For control groups, placebos and standard care, the protocol should state the operational rule, who applies it, when it is applied and what source documents demonstrate compliance. The investigators should also consider how a different choice would change the eligible population, comparison, timing, measurement or interpretation. A pilot review of realistic records or participant pathways can reveal ambiguities before they become irreversible exclusions or post hoc analytical choices. The decision should be reviewed across sites and subgroups because a rule that works in one clinic may operate differently where referral, resources or disease spectrum differ. Any permitted exception should be explicit, dated and reported with its frequency and likely consequence.
Decision 4: Could the comparator itself change behaviour or outcomes?. This point should be resolved before recruitment, extraction or assignment begins. For control groups, placebos and standard care, the protocol should state the operational rule, who applies it, when it is applied and what source documents demonstrate compliance. The investigators should also consider how a different choice would change the eligible population, comparison, timing, measurement or interpretation. A pilot review of realistic records or participant pathways can reveal ambiguities before they become irreversible exclusions or post hoc analytical choices. The decision should be reviewed across sites and subgroups because a rule that works in one clinic may operate differently where referral, resources or disease spectrum differ. Any permitted exception should be explicit, dated and reported with its frequency and likely consequence.
Decision 5: How variable is standard care across sites and time?. This point should be resolved before recruitment, extraction or assignment begins. For control groups, placebos and standard care, the protocol should state the operational rule, who applies it, when it is applied and what source documents demonstrate compliance. The investigators should also consider how a different choice would change the eligible population, comparison, timing, measurement or interpretation. A pilot review of realistic records or participant pathways can reveal ambiguities before they become irreversible exclusions or post hoc analytical choices. The decision should be reviewed across sites and subgroups because a rule that works in one clinic may operate differently where referral, resources or disease spectrum differ. Any permitted exception should be explicit, dated and reported with its frequency and likely consequence.
The approach should be chosen because its structure answers the research question, not because the available dataset happens to resemble a familiar table. The investigator should state the target population, time origin, comparison, outcome and intended measure before collecting or extracting data.
Design and participant pathway
Trial comparator
Core structure: Assign a clinically relevant alternative strategy that makes the intended treatment contrast interpretable and ethically acceptable.
Best suited for: Superiority, comparative-effectiveness, non-inferiority and component-effect questions.
Principal threats: Underdescribed usual care, inadequate active treatment, unethical placebo, contamination, differential contact and comparator drift.
Comparator selection should involve clinicians, patients, policymakers and trialists. A three-arm design can include experimental treatment, active control and placebo when necessary, but increases sample size and multiplicity. In non-inferiority trials, poor adherence or treatment dilution can falsely favour similarity, making trial conduct especially important.
Protocol specification
Decisions to prespecify
- State the decision and treatment contrast.
- Describe control content, provider, dose, schedule and monitoring.
- Define permitted rescue and co-interventions.
- Measure variation and contamination in standard care.
- Specify non-inferiority or equivalence margins when relevant.
- Plan interpretation if the comparator changes during the trial.
Protocol item 1: State the decision and treatment contrast. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
Protocol item 2: Describe control content, provider, dose, schedule and monitoring. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
Protocol item 3: Define permitted rescue and co-interventions. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
Protocol item 4: Measure variation and contamination in standard care. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
Protocol item 5: Specify non-inferiority or equivalence margins when relevant. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
Protocol item 6: Plan interpretation if the comparator changes during the trial. This item requires a reproducible definition rather than a broad intention. The study manual should identify the responsible role, data field or procedural record, permissible time window, quality check and response to deviations. Where judgement is unavoidable, assessors should receive examples and escalation rules, and a sample of decisions should be reviewed for consistency. The analysis dataset should retain enough provenance to distinguish planned exclusions, measurement failure, participant withdrawal and genuinely absent information.
A protocol should make these decisions before outcome-dependent choices become tempting. It should also distinguish the design population from the analysis population, document exclusions after enrolment or sampling, and explain how missing or indeterminate observations will be handled. Any deviation should be dated, justified and retained in the study record.[2–4]
Measurements, timing and analysis interface
Treatment receipt should be measured in every group. Usual-care documentation can include contacts, referrals, prescriptions and educational materials. Expectation or satisfaction measures may help describe experience but should not be used to statistically “correct” the primary effect without causal justification. Adverse events should be collected comparably.
The analysis should reflect how participants or clusters entered the study, how observations are related, and how the effect or performance measure was defined. Statistical adjustment cannot repair a comparison that was invalid at the design stage. Conversely, a sound design can still be undermined by an analysis that ignores matching, clustering, censoring, sampling fractions or prespecified thresholds.
Worked example
Routine care or reminder-only?
The primary policy question is whether the full navigation package should replace current discharge practice, so routine care is the main comparator. A reminder-only arm would answer a different component question and require a larger three-arm trial. The team documents routine discharge materials, appointment practices and external reminders at each site and tracks changes during recruitment.
The example should be interpreted in the population and time frame created by the design. The numerical result does not by itself establish causation, transportability or clinical usefulness; those conclusions require additional assumptions and evidence.
Appraising methodological quality
Questions for critical appraisal
- Relevance: Does the comparator match the intended decision?
- Ethics: Are effective treatments and rescue options protected?
- Specification: Can the control strategy be reproduced?
- Fidelity: Was the comparator actually delivered?
- Drift: Did standard care or policy change during the trial?
A reporting guideline can improve transparency, but it is not a substitute for sound design. Appraisal should ask whether the reported methods could generate an unbiased, clinically meaningful answer—not merely whether every checklist item has been mentioned.[3–6]
Suggested reporting
Reporting should identify the design in the title or abstract when appropriate, describe the source and flow of participants, define all key variables, report missing and indeterminate observations, and present estimates with uncertainty. The direction and denominator of every comparison must be explicit.
Ethical and governance considerations
Non-inferiority requires assay sensitivityMMed extension
A non-inferiority conclusion is credible only if the trial could have detected a meaningful difference. Appropriate margin selection, an effective active comparator, adherence, outcome sensitivity and consistency with historical evidence are critical. Both intention-to-treat and per-protocol analyses are commonly examined, but neither substitutes for sound conduct.
Common mistakes
Knowledge check
What does navigation versus reminder-only estimate?
Answer and reasoning
The incremental effect of the additional navigation components beyond reminders, not the effect versus current practice.
Why measure usual care?
Answer and reasoning
Its content and variation define the comparison and may change across sites or time.
Does a non-significant superiority result establish equivalence?
Answer and reasoning
No. Equivalence or non-inferiority requires a prespecified margin, suitable design and appropriate confidence-interval interpretation.
When can an attention control be active?
Answer and reasoning
Contact, monitoring or supportive conversation can itself change behaviour or outcomes.
Key take-home messages
Key take-home messages
- Choose the comparator from the decision, not convenience.
- Describe control conditions with the same precision as interventions.
- Protect effective care and rescue options.
- Measure fidelity, contamination and drift.
- Do not confuse no evidence of superiority with equivalence.
References
- Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. https://doi.org/10.1136/bmj-2024-081123
- Butcher NJ, Monsour A, Mew EJ, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477. https://doi.org/10.1136/bmj-2024-081477
- International Council for Harmonisation. ICH harmonised guideline E6(R3): Guideline for Good Clinical Practice. Geneva: ICH; 2025. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
- Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. https://doi.org/10.1136/bmj.g1687
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA. 2024;333(1):71–74. https://doi.org/10.1001/jama.2024.21972
- Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials. JAMA. 2012;308(24):2594–2604. https://doi.org/10.1001/jama.2012.87802
These materials support learning and research planning. They require adaptation to the study context and do not replace methodological, statistical, ethical, or regulatory consultation.